Cherifi François, Awada Ahmad
Oncology Medicine department, François Baclesse Center, Caen, France.
Oncology Medicine Department of Chirec Cancer Institute, Université Libre de Bruxelles Brussels, Belgium.
Crit Rev Oncol Hematol. 2025 May;209:104679. doi: 10.1016/j.critrevonc.2025.104679. Epub 2025 Mar 3.
Thyroid cancer (TC) is the most common endocrine malignancy. Most patients will be treated and cured by surgery but a low percentage will develop advanced disease. The treatment of advanced disease is at first the use of radioiodine treatment in differentiated cancer then at progression will rely on molecular alterations and consequently in targeted treatments. In this review, we will explore the most frequent molecular alterations of each histological subtype: differentiated thyroid cancer (DTC), anaplastic thyroid cancer (ATC), medullary thyroid cancers (MTC) and clinically tested and approved treatment. We will also report the clinical and preclinical perspective in this field.
甲状腺癌（TC）是最常见的内分泌恶性肿瘤。大多数患者将通过手术得到治疗并治愈，但仍有一小部分会发展为晚期疾病。晚期疾病的治疗首先是对分化型癌使用放射性碘治疗，病情进展时则依赖分子改变，进而采用靶向治疗。在本综述中，我们将探讨每种组织学亚型最常见的分子改变：分化型甲状腺癌（DTC）、未分化甲状腺癌（ATC）、髓样甲状腺癌（MTC）以及经过临床测试和批准的治疗方法。我们还将报告该领域的临床和临床前研究情况。
